Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well
tolerated, but associated with various statin-associated symptoms (SAS), including statin …

Background The objective of this pilot study was to evaluate the comparative efficacy of
alternate-day dosing of atorvastatin compared with the standard once-daily dose based on …

Background: Atorvastatin is a synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase. In placebo-controlled trials, it has been shown to achieve significant …

This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐
response effects and safety of once‐daily administration of pravastatin, a new inhibitor of 3 …

The prevalence of coronary heart disease (CHD) has been increasing in the past few
decades in Japan, as it has in industrialised countries worldwide. CHD risk can be …

Background: Although the effect of statins on lowering low-density lipoprotein cholesterol
(LDL-C) has been extensively studied, their hypotriglyceridemic capacity is not fully …

This randomized, multicenter, double-blind parallel-group study was performed to evaluate
the lipid-altering efficacy and safety of simvastatin 80 mg/day, a dose twice the current …

This article reviews the safety of statins, with emphasis on high-dose atorvastatin (80 mg),
the agent with the most efficacy data for clinical outcomes. Although elevated levels of …

Simvastatin is a potent lipid-lowering agent that has proven highly effective in the treatment
of primary hypercholesterolaemia. This report extends the data on controlled clinical trials …

We report the results of an open multicenter study which evaluated the efficacy, safety, and
tolerability of simvastatin in a large cohort of patients with primary hypercholesterolemia …